Company History
Ta Fong Pharmaceutical’s development reflects the transformation of Taiwan’s pharmaceutical industry from local manufacturing to internationally aligned standards.
Today
Sustained Growth
Expanded to nearly 200 products across multiple dosage forms, with continuous enhancement of manufacturing and quality capabilities.
2010s
Specialized Manufacturing
Established Taiwan’s only sterile production line for female hormone injectables, creating a unique competitive advantage.
2013
PIC/S GMP Certification
Achieved PIC/S GMP certification and has maintained compliance with international standards since.
2010
International Expansion
Began expanding into overseas markets, establishing partnerships and exporting to Southeast Asia.
2005
Hospital Market Entry
Successfully entered major hospital systems and group purchasing tenders, expanding clinical market presence.
2004
Quality System Advancement
Manufacturing standards were progressively upgraded from GMP to cGMP. Ta Fong successfully completed the three-phase cGMP validation and received a national award recognizing excellence in pharmaceutical quality systems.
2000
R&D Advancement
Initiated development of bioequivalence (BE) products, strengthening regulatory compliance and product development capabilities.
1995
Market Expansion
With the implementation of Taiwan’s National Health Insurance, Ta Fong expanded into the generic pharmaceutical market and established dedicated hospital and clinic sales divisions.
1994
International Collaboration
Entered into a technical collaboration with Roche, enhancing manufacturing technology and quality standards.
1987
GMP Upgrade
Commissioned a GMP-certified facility, establishing a modern pharmaceutical manufacturing and quality management system.
1970s-1980s
Industry Foundation
Expanded manufacturing capabilities and product portfolio, strengthening its position within Taiwan’s pharmaceutical cluster in Changhua.
1974
Corporate Transformation
Renamed Ta Fong Pharmaceutical under the leadership of Mr. Huo-Cheng Yeh, with manufacturing operations relocated to Changhua, a key pharmaceutical hub in Taiwan.
